Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Show more

Location: 1560 Trapelo Road, Waltham, MA, 02451, United States | Website: https://www.dyne-tx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.277B

52 Wk Range

$6.36 - $47.45

Previous Close

$9.40

Open

$9.50

Volume

1,691,146

Day Range

$8.95 - $9.60

Enterprise Value

427.9M

Cash

677.5M

Avg Qtr Burn

-79.93M

Insider Ownership

0.56%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.